Ultime notizie per Instil Bio (NASDAQ:TIL) Azioni

INSTIL BIO INC

Instil Bio

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Instil Bio Inc

Till Capital Corp

Interface Inc

Listed Funds Trust Teucrium Agricultural Strategy No K-1 ETF

FlexShares Mornigstar US Market Factors Tilt Index Fund ETF

Barclays analyst Jeff Kessler maintains Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) with a Equal-Weight and raises the price target from $21 to $24.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Dine Brands Global, Raises Price Target to $24

Piper Sandler analyst Jason Bednar maintains KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) with a Neutral and lowers the price target from $4.5 to $3.5.

KRMD

Piper Sandler Maintains Neutral on KORU Medical Systems, Lowers Price Target to $3.5

WIIM

Devon Energy shares are trading after the company announced it sold the equity interest in the Matterhorn Express pipeline. Barclays raised its price target on the stock from $38 to $40.

Barclays analyst Mario Lu maintains Corsair Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSR#NASDAQ">CRSR</a>) with a Overweight and lowers the price target from $12 to $10.

CRSR

Barclays Maintains Overweight on Corsair Gaming, Lowers Price Target to $10

Piper Sandler analyst Matt O'Brien maintains OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Overweight and lowers the price target from $40 to $30.

KIDS

Piper Sandler Maintains Overweight on OrthoPediatrics, Lowers Price Target to $30

Barclays analyst Tavy Rosner maintains CEVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>) with a Overweight and lowers the price target from $40 to $30.

CEVA

Barclays Maintains Overweight on CEVA, Lowers Price Target to $30

Piper Sandler analyst Paul Newsome maintains ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) with a Neutral and raises the price target from $18 to $25.

Piper Sandler Maintains Neutral on ProAssurance, Raises Price Target to $25

Trading Ideas

NFLX

Live On CNBC, Steve Weiss Announces Bought More Netflix

Barclays analyst Adam Seiden maintains Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) with a Overweight and lowers the price target from $54 to $50.

BLBD

Barclays Maintains Overweight on Blue Bird, Lowers Price Target to $50

Barclays analyst Jeffrey Bernstein maintains Bloomin Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) with a Equal-Weight and lowers the price target from $9 to $8.

BLMN

Barclays Maintains Equal-Weight on Bloomin Brands, Lowers Price Target to $8

BCE shares are trading higher following Q1 reported financial results.

Piper Sandler analyst Patrick Moley maintains MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) with a Neutral and lowers the price target from $213 to $202.

MKTX

Piper Sandler Maintains Neutral on MarketAxess Holdings, Lowers Price Target to $202

Tutor Perini shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 EPS guidance with its midpoint above estimates.

QDEL

QuidelOrtho shares are trading higher after the company reported better-than-expected Q1 financial results. Also, Jefferies upgraded the stock from Hold to Buy and announced a $44 price target.

Nexstar Media Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>) shares are trading higher on Thursday. The company reported first-quarter FY25 net revenue decrease of 3.9% year over year (Y/Y) to $1.234 billion, which <a href="https://www.benzinga.com/pressreleases/25/05/b45280891/nexstar-media-group-reports-first-quarter-net-revenue-of-1-23-billion" target="_blank" rel="noopener">align</a><a href="https://www.benzinga.com/pressreleases/25/05/b45280891/nexstar-media-group-reports-first-quarter-net-revenue-of-1-23-billion" target="_blank" rel="noreferrer noopener">s with the consensus</a>.
Nexstar Media Group owns a diverse portfolio of media brands, including national television networks like The CW and NewsNation and digital assets like The Hill and NewsNationNow.com.
Revenues from Advertising declined 10.2% Y/Y to $460 million due to a $32 million drop in political advertising and a $20 million reduction in non-political advertising revenue on the softness of the advertising markets.
Distribution revenue remained almost flat year over year at $762 million. This segment benefited from annual rate increases, higher vMVPD subscribers, and CW affiliation additions.
Also Read: <a href="https://www.benzinga.com/news/25/04/45105008/nexstar-nxst-stock-dips-as-short-seller-warns-of-kodak-moment" target="_blank" rel="noreferrer noopener">Nexstar Stock Dips As Short Seller Warns Of &#8220;Kodak Moment&#8221;</a>
Adjusted EBITDA fell 15.7%&nbsp;Y/Y to&nbsp;$381&nbsp;million, and the margin contracted to&nbsp;30.9%&nbsp;from&nbsp;35.2%&nbsp;a year ago.
EPS was&nbsp;$3.37, down from&nbsp;$5.16 in the prior-year quarter, but it beat the consensus estimate of&nbsp;$3.35.
Adjusted free cash flow totaled&nbsp;$348 million, down from&nbsp;$389 million in the prior year quarter. As of March 31, 2025, cash stood at&nbsp;$253 million.
Dividend: The Board of Directors raised the quarterly cash dividend by 10% to $1.86 per share, payable on June 2, to shareholders of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45190320/nexstar-media-group-declares-quarterly-cash-dividend-of-1-86-per-share" rel="noreferrer noopener">record as of May 19, 2025</a>.
Buyback: The company repurchased shares worth&nbsp;$75&nbsp;million&nbsp;in the quarter.
Nexstar CEO&nbsp;Perry A. Sook&nbsp;said, &#8220;As the nation&#8217;s largest local broadcaster, we strategically use our scale to drive strong operating results and cash flow and facilitate organic growth initiatives as we further elevate The CW and NewsNation to top-tier networks.&#8221;
&#8221;For the balance of 2025, we remain focused on renewing distribution contracts representing approximately 60% of our subscriber base in total for the year, continuing our path towards profitability at The CW, preparing for the 2026 political cycle, and pursuing deregulation.&#8221;
Investors can gain exposure to the stock via&nbsp;Alpha Architect U.S. Quantitative Value ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVAL#NASDAQ">QVAL</a>) and WisdomTree U.S. SmallCap Quality Growth Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSML#NASDAQ">QSML</a>).
Price Action: Nexstar shares are up 8.45% to $169.07 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/45201601" target="_blank" rel="noreferrer noopener">Trump Wants &#8216;Movies Made In America Again&#8217;: Here&#8217;s What Tariffs On Films Could Mean For Disney, Netflix Stock</a></li>
</ul>
Image by metamorworks via Shutterstock

Earnings

Equities

Dividends

Small Cap

Movers

NXST

QSML

QVAL

NewsNation Parent Nexstar Raises Dividend Despite Q1 Revenue Decline, Stock Soars

Barclays analyst Benjamin Theurer maintains Beyond Meat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) with a Underweight and lowers the price target from $3 to $2.

BYND

Barclays Maintains Underweight on Beyond Meat, Lowers Price Target to $2

Occidental Petroleum shares are trading higher. The company announced it reduced its debt by $2.3 billion year-to-date.

Barclays analyst Brandon Oglenski maintains Allegiant Travel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) with a Equal-Weight and lowers the price target from $60 to $52.

ALGT

Barclays Maintains Equal-Weight on Allegiant Travel, Lowers Price Target to $52

Cenovus Energy shares are trading higher. The company reported Q1 financial results.

Barclays analyst Andrew Mok maintains Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) with a Underweight and raises the price target from $2 to $3.

Barclays Maintains Underweight on Agilon Health, Raises Price Target to $3

Press Releases

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Health Care

General

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Comments

Instil Bio

Notizie

Ultime notizie per Instil Bio (NASDAQ:TIL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO